相关实验视频
Updated: Sep 20, 2025

12:08
Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
19.0K
在英国,在接受第一代或第二代基底胰岛素治疗的2型糖尿病成年人中,医疗保健的利用率和成本
Neil Holden1, Onyinye Diribe2, Karen Palmer2
1Sanofi UK, Reading, UK Neil.Holden@sanofi.com.
BMJ open diabetes research & care
|May 29, 2025
概括
像Gla-300这样的第二代基础胰岛素 (BI) 类型在英国为2型糖尿病 (T2D) 患者提供经济和临床益处. 与第一代BI相比,切换到Gla-300减少了医疗保健资源的使用和成本,特别是通过降低低血糖事件.
科学领域:
- 药物经济学 药物经济学
- 糖尿病管理 糖尿病管理
- 临床研究 临床研究
背景情况:
- 2型糖尿病 (T2D) 的患病率不断上升,需要有效的基础胰岛素 (BI) 治疗.
- 关于第二代BI同类与第一代BI对英国经济影响的数据有限.
- 在最大限度地减少并发症的同时,优化血糖控制对于T2D管理至关重要.
研究的目的:
- 为了比较第二代BI类似物 (glargine 300 U/mL [Gla-300], degludec) 与第一代BI在英国T2D患者中的经济影响和医疗资源利用率 (HCRU).
- 评估低血糖的发生率和相关的医疗保健费用.
主要方法:
- 使用英国临床实践研究数据链接 (CPRD) Aurum与医院情节统计数据相关的回顾性观察性研究.
- 包括13,975名患有T2D的成年人,他们从第一代BI切换到另一个第一代BI,Gla-300,或 degludec.
- 倾向性得分加权均衡的基线特征;HCRU和成本进行了比较.
主要成果:
- 切换到Gla-300的患者显示HCRU显著降低.
- 与第一代BI (16.4%) 和 degludec (11.7%) 相比,Gla-300组的低血糖相关医疗保健遭遇较少 (9.1%).
- 格拉-300的总直接成本比第一代BI低17%,比 degludec低60%.
结论:
- 通过减少T2D患者的低血糖事件,Gla-300可能会提供临床益处.
- 与第一代BI相比,Gla-300通过较低的医疗保健成本提供了潜在的经济优势.
- 研究结果支持Gla-300作为英国T2D管理的成本有效的治疗选择.
相关概念视频
Insulin: Dosing Regimen and Adverse Effects
271
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
271
Diabetes Mellitus: Type 2 and Gestational
3.0K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
3.0K
Diabetes Mellitus: Overview and Type I Subtype
3.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
3.3K
Diabetes: Management and Pharmacotherapy
412
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
412
Diabetes: Symptoms, Diagnosis, and Complications
715
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
715
Oral Hypoglycemic Agents: Sulfonylureas
353
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
353

